Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Condition(s):Interstitial Lung Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLast Updated:June 2, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Interstitial Lung Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLast Updated:June 2, 2020Completed
Condition(s):Granulomatosis With PolyangitisLast Updated:November 22, 2019Recruiting
Condition(s):Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisLast Updated:January 30, 2024Not yet recruiting
Condition(s):Glomerulonephritis AcuteLast Updated:November 14, 2023Completed
Condition(s):ANCA Associated VasculitisLast Updated:December 14, 2023Recruiting
Condition(s):ANCA Associated VasculitisLast Updated:December 14, 2022Recruiting
Condition(s):ANCA-associated VasculitisLast Updated:October 13, 2023Recruiting
Condition(s):VasculitisLast Updated:December 13, 2018Terminated
Condition(s):Systemic VasculitisLast Updated:May 3, 2018Unknown status
Condition(s):Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)Last Updated:January 25, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.